Nothing Special   »   [go: up one dir, main page]

BR112016030368A2 - composição oftálmica - Google Patents

composição oftálmica

Info

Publication number
BR112016030368A2
BR112016030368A2 BR112016030368-7A BR112016030368A BR112016030368A2 BR 112016030368 A2 BR112016030368 A2 BR 112016030368A2 BR 112016030368 A BR112016030368 A BR 112016030368A BR 112016030368 A2 BR112016030368 A2 BR 112016030368A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
ophthalmic
composition
Prior art date
Application number
BR112016030368-7A
Other languages
English (en)
Other versions
BR112016030368B1 (pt
Inventor
I. Ostrow Gregory
J. Widder Kenneth
S. Baker David
Original Assignee
Sydnexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016030368(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sydnexis, Inc. filed Critical Sydnexis, Inc.
Publication of BR112016030368A2 publication Critical patent/BR112016030368A2/pt
Publication of BR112016030368B1 publication Critical patent/BR112016030368B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016030368-7A 2014-06-24 2015-06-23 Composição oftálmica e uso da mesma BR112016030368B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US62/016,502 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US62/096,433 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US62/151,926 2015-04-23
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
US14/726,139 2015-05-29
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Publications (2)

Publication Number Publication Date
BR112016030368A2 true BR112016030368A2 (pt) 2018-07-17
BR112016030368B1 BR112016030368B1 (pt) 2022-11-01

Family

ID=54868660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030368-7A BR112016030368B1 (pt) 2014-06-24 2015-06-23 Composição oftálmica e uso da mesma

Country Status (20)

Country Link
US (11) US9421199B2 (pt)
EP (3) EP4115884A1 (pt)
JP (4) JP6678362B2 (pt)
KR (4) KR20200001612A (pt)
CN (3) CN106572998B (pt)
BR (1) BR112016030368B1 (pt)
CA (1) CA2953363C (pt)
DK (1) DK3160471T3 (pt)
ES (1) ES2924243T3 (pt)
HR (1) HRP20220972T1 (pt)
HU (1) HUE059521T2 (pt)
IL (1) IL249643B (pt)
LT (1) LT3160471T (pt)
PL (1) PL3160471T3 (pt)
PT (1) PT3160471T (pt)
RS (1) RS63486B1 (pt)
SG (3) SG10201913976SA (pt)
SI (1) SI3160471T1 (pt)
TW (2) TW202412797A (pt)
WO (1) WO2015200361A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2887923T1 (sl) 2012-08-24 2023-09-29 Sun Pharmaceutical Industries Limited Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
AU2017227585C1 (en) 2016-02-29 2022-05-26 Sun Pharmaceutical Industries Limited Topical cyclosporine-containing formulations and uses thereof
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
ES2929368T3 (es) * 2016-05-25 2022-11-28 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
AU2018224426B2 (en) * 2017-02-21 2023-05-18 Singapore Health Services Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
EA201992234A1 (ru) * 2017-03-23 2020-02-05 Сингапур Хелт Сервисиз Пте Лтд Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента
SG11201908478SA (en) 2017-03-27 2019-10-30 Regeneron Pharma Sterilisation method
RU2745603C1 (ru) 2017-05-11 2021-03-29 Невакар Инк. Фармацевтические композиции атропина
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
CN111093648A (zh) 2017-07-20 2020-05-01 艾伦实验室股份有限公司 治疗近视的组合物和方法
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
WO2019136358A1 (en) 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
CN109157503B (zh) * 2018-09-25 2019-08-16 沈阳兴齐眼药股份有限公司 防治nitm的药物组合物及其医药用途
EP3701938B8 (en) 2019-03-01 2024-02-21 Medivis S.R.L. Ophthalmic formulations based on atropine
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
EP3996644A4 (en) * 2019-07-11 2023-07-26 University of Utah Research Foundation MULTIPLE SUBSTANCE EYE FORMULATIONS AND TREATMENT METHODS
US20220411482A1 (en) * 2019-11-15 2022-12-29 Silk Technologies, Ltd. Stable formulations of silk-derived protein
CN115279378A (zh) * 2019-12-16 2022-11-01 西德奈克西斯公司 包含d2o的眼用组合物
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
JP2024505517A (ja) * 2021-01-28 2024-02-06 グラウコス コーポレイション 製剤
EP4288049A1 (en) * 2021-02-04 2023-12-13 Sydnexis, Inc. Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
CA3211874A1 (en) * 2021-03-16 2022-09-22 Kumaresh Soppimath Multi-dose container for ophthalmic compositions
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4426353A2 (en) * 2021-11-05 2024-09-11 Calm Water Therapeutics LLC Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
WO2023215407A2 (en) * 2022-05-03 2023-11-09 Iview Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (pt) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (pt) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (pt) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
EP1206283A2 (en) 1999-05-17 2002-05-22 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
JP5000835B2 (ja) 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
BR0210013A (pt) 2001-05-25 2004-08-10 Valley Forge Pharmaceuticals Gel oftálmico de pirenzepina
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
EP1660056A4 (en) 2003-08-15 2008-12-17 Arius Two Inc BIODEGRADABLE ADHESIVE DRUG DELIVERY SYSTEM FOR MUCOUS MEMBRANES
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2005209304B2 (en) 2004-01-27 2010-08-26 Warsaw Orthopedic, Inc. Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
CA2597219C (en) 2005-02-04 2014-04-15 Auburn University Contact drug delivery system
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
EP1954254A4 (en) 2005-11-01 2010-12-22 Harvard College MODULATION OF ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) * 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
EP2110132B1 (de) 2008-04-20 2014-01-22 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
CA2746491C (en) 2008-12-11 2018-01-16 Massachusetts Institute Of Technology Contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US8945101B2 (en) * 2010-04-30 2015-02-03 Seros Medical, Llc Method and apparatus for treatment of ocular tissue using combine modalities
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
EA201390120A3 (ru) 2010-07-15 2013-09-30 Коринтиан Офтэлмик, Инк. Доставка офтальмологических лекарственных средств
MX339173B (es) 2010-07-15 2016-05-12 Corinthian Ophthalmic Inc Dispositivo generador de gotas.
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
US20120225952A1 (en) 2011-03-03 2012-09-06 Warner Kevin S Non-aqueous silicone-based ophthalmic formulations
CN103687594A (zh) 2011-04-05 2014-03-26 奥普托索夫有限公司 眼科治疗
US20150038473A1 (en) 2011-05-12 2015-02-05 Foresight Biotherapeutics, Inc. Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
IN2014MN02236A (pt) 2012-05-11 2015-07-24 Cipla Ltd
SG11201407428YA (en) 2012-05-14 2014-12-30 Eyenovia Inc Laminar flow droplet generator device and methods of use
MX2014013962A (es) 2012-05-15 2015-06-17 Eyenovia Inc Dispositivos eyectores, métodos, accionadores y circuitos para los mismos.
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
SI2887923T1 (sl) 2012-08-24 2023-09-29 Sun Pharmaceutical Industries Limited Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
EP2978453B1 (en) 2013-03-29 2018-10-31 Onefocus Technology, LLC Drug delivery from contact lenses with a fluidic module
ES2871116T3 (es) 2013-05-06 2021-10-28 Kaohsiung Chang Gung Memorial Hospital Composición farmacéutica de un AINE y atropina
KR102341908B1 (ko) 2013-05-17 2021-12-23 인사이트 코포레이션 Ｊａｋ 저해제로서 비피라졸 유도체
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
AU2015301761B2 (en) 2014-08-13 2020-05-21 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
ES2929368T3 (es) 2016-05-25 2022-11-28 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
CA3029281A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US10888546B2 (en) 2016-09-19 2021-01-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2018224426B2 (en) 2017-02-21 2023-05-18 Singapore Health Services Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
RU2745603C1 (ru) 2017-05-11 2021-03-29 Невакар Инк. Фармацевтические композиции атропина
CN111093648A (zh) 2017-07-20 2020-05-01 艾伦实验室股份有限公司 治疗近视的组合物和方法
US20200345542A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
CN115279378A (zh) 2019-12-16 2022-11-01 西德奈克西斯公司 包含d2o的眼用组合物

Also Published As

Publication number Publication date
EP4115884A1 (en) 2023-01-11
CN106572998A (zh) 2017-04-19
EP3689350A1 (en) 2020-08-05
US20240165098A1 (en) 2024-05-23
TW202412797A (zh) 2024-04-01
TWI763620B (zh) 2022-05-11
KR102710491B1 (ko) 2024-09-25
US10842787B2 (en) 2020-11-24
US20190091213A1 (en) 2019-03-28
US11883390B2 (en) 2024-01-30
DK3160471T3 (da) 2022-08-15
HRP20220972T1 (hr) 2022-11-25
US11890277B2 (en) 2024-02-06
US10076515B2 (en) 2018-09-18
US20190298707A1 (en) 2019-10-03
ES2924243T3 (es) 2022-10-05
CN106572998B (zh) 2019-11-08
US20230092957A1 (en) 2023-03-23
KR102506109B1 (ko) 2023-03-03
US20230093205A1 (en) 2023-03-23
US11896588B2 (en) 2024-02-13
SI3160471T1 (sl) 2022-10-28
JP2024050526A (ja) 2024-04-10
PL3160471T3 (pl) 2022-09-26
US20160339007A1 (en) 2016-11-24
CA2953363C (en) 2024-02-27
IL249643B (en) 2021-10-31
SG10201913976SA (en) 2020-03-30
KR20200001612A (ko) 2020-01-06
JP2022062045A (ja) 2022-04-19
KR20170018962A (ko) 2017-02-20
BR112016030368B1 (pt) 2022-11-01
SG10201707617VA (en) 2017-10-30
TW201613588A (en) 2016-04-16
US20210059998A1 (en) 2021-03-04
WO2015200361A1 (en) 2015-12-30
US9770447B2 (en) 2017-09-26
US11596625B2 (en) 2023-03-07
JP6678362B2 (ja) 2020-04-08
US10864208B2 (en) 2020-12-15
KR20240144477A (ko) 2024-10-02
US9421199B2 (en) 2016-08-23
US20150366854A1 (en) 2015-12-24
TW202237110A (zh) 2022-10-01
US20180042911A1 (en) 2018-02-15
SG11201610682UA (en) 2017-01-27
LT3160471T (lt) 2022-11-10
JP2017522292A (ja) 2017-08-10
US20230091109A1 (en) 2023-03-23
HUE059521T2 (hu) 2022-11-28
JP2020097599A (ja) 2020-06-25
JP7505888B2 (ja) 2024-06-25
RS63486B1 (sr) 2022-09-30
CA2953363A1 (en) 2015-12-30
PT3160471T (pt) 2022-08-09
EP3160471A1 (en) 2017-05-03
CN115192520A (zh) 2022-10-18
US20180193326A1 (en) 2018-07-12
KR20210116688A (ko) 2021-09-27
IL249643A0 (en) 2017-02-28
CN110638749A (zh) 2020-01-03
US10201534B2 (en) 2019-02-12
EP3160471B1 (en) 2022-06-01
EP3160471A4 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
BR112016030368A2 (pt) composição oftálmica
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3222714T3 (da) Phytasemutanter
DK3006072T3 (da) Karadgang
DK3215173T3 (da) Glycopeptidsammensætninger
DK3119396T3 (da) Muscarinreceptoragonister
FR3024363B1 (fr) Composition thermogelifiable
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
CL2017000639A1 (es) Composición
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DK3216451T3 (da) Oftalmisk vandig sammensætning
DE112015005041A5 (de) Gargerätevorrichtung
DK3200827T3 (da) Sammensætninger
DE102014000623A8 (de) Halbhohlnietelement
DK3217964T3 (da) Sammensætning
DK3009858T3 (da) Skyradar
FR3019552B1 (fr) Composition filmogene
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: SYDNEXIS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/06/2015, OBSERVADAS AS CONDICOES LEGAIS